Jazz Pharmaceuticals(JAZZ) - 2024 Q4 - Annual Report

Product Development and Pipeline - The company reported approximately 14,150 patients taking Xywav by the end of 2024, including about 10,250 patients with narcolepsy and approximately 3,900 patients with idiopathic hypersomnia (IH) [417]. - Xywav is recognized as the first and only FDA-approved therapy for the treatment of IH in adults, with seven years of orphan drug exclusivity extending through August 2028 [415]. - The company acquired Epidiolex in May 2021, expanding its neuroscience business with a high-growth childhood-onset epilepsy franchise [418]. - Rylaze was launched in the U.S. in July 2021 and is the only recombinant erwinia asparaginase product approved in the U.S. [419]. - The company focuses on research and development activities within neuroscience and oncology therapeutic areas to drive sustainable growth [408]. - The company aims to identify and develop differentiated therapies for patient populations with high unmet needs [407]. - The company continues to expand its pipeline to achieve a valuable portfolio of durable, highly differentiated products [410]. - Zepzelca was launched in the U.S. in early 2020 for treating SCLC patients after platinum-based chemotherapy, with ongoing promotional efforts targeting SCLC-treating physicians [420]. - A Phase 3 trial in collaboration with Roche for Zepzelca and Tecentriq showed statistically significant benefits, with plans for an sNDA submission in the first half of 2025 [420]. - Zanidatamab received FDA approval in November 2024 for second-line HER2-positive BTC, with a total potential payment to Zymeworks of $1.76 billion under the licensing agreement [427]. - The ongoing Phase 3 trials for zanidatamab include first-line HER2-positive GEA and BTC, with additional trials for previously treated HER2-positive breast cancer [436]. - JZP441, an orexin-2 receptor agonist, achieved initial proof-of-concept in a Phase 1 trial, with plans for a Phase 1b trial in narcolepsy Type 1 patients in 2025 [435]. - The company has multiple ongoing clinical trials for zanidatamab, including a pivotal Phase 2 trial for advanced HER2-amplified BTC, with a BLA submission completed in March 2024 [427]. - The company is exploring options for the suvecaltamide program after recent trials did not achieve statistical significance on primary endpoints [434]. Financial Performance - Product sales, net for 2024 reached$3,821,164, a 2% increase from 2023's $3,736,943, which was a 3$3,641,429 [454]. - Royalties and contract revenues surged to $247,786 in 2024, a 155$97,261 in 2023, which was a 442% increase from $17,945 in 2022 [454]. - Xywav product sales increased by 16$1,473,202, driven by an 8% increase in patients taking the drug for narcolepsy and a 41% increase for idiopathic hypersomnia (IH) compared to 2023 [458]. - Xyrem product sales decreased by 59% in 2024 to $233,816, primarily due to competition from high-sodium oxybate and the adoption of Xywav [455]. - Research and development expenses rose to$884,000 in 2024, a 4% increase from $849,658 in 2023, with clinical studies and outside services costs contributing significantly [467]. - Selling, general and administrative expenses increased to$1,385,294 in 2024, a 3% increase from $1,343,105 in 2023, driven by higher compensation-related expenses and increased investment in sales and marketing [464]. - The gross margin as a percentage of net product sales was 88.3$500 million, replacing the previous program which had an authorized repurchase amount of $1.5 billion [2]. - The company repurchased 2.8 million ordinary shares for$311.4 million in 2024, with an average purchase price of $110.06 per share [483]. - The New Repurchase Program authorized in July 2024 allows for ongoing share repurchases without an expiration date [483]. Debt and Financing - The principal amount of Tranche B-1 and B-2 Dollar Term Loans each totaled$2.7 billion [491]. - The applicable margin for Tranche B-2 Dollar Term Loans is 2.25% for Term SOFR borrowings, a decrease of 75 basis points from Tranche B-1 [492]. - As of December 31, 2024, the interest rate on Tranche B-2 Dollar Term Loans was 6.61% and the effective interest rate was 8.27% [492]. - The Initial Revolving Credit Facility was increased from $500.0 million to$885.0 million [493]. - Interest on the 2030 Notes is payable at a rate of 3.125% per year, maturing on September 15, 2030 [504]. - The 2026 Notes have an interest rate of 2.00% per year and mature on June 15, 2026 [509]. - The 2024 Notes were repaid in full on August 15, 2024, totaling $575.0 million [513]. - The interest rate on the Secured Notes was 4.375$91.4 million in 2024, down from $119.9 million in 2023 and$158.6 million in 2022, primarily due to changes in income mix across jurisdictions [475]. - Regulatory scrutiny and potential healthcare reforms may impact pricing and reimbursement for the company's products, affecting overall revenue [450]. Cash Flow and Investments - Cash flows from operations were $1.4 billion in 2024, an increase of$303.9 million compared to $1.1 billion in 2023 [484]. - Net cash used in investing activities increased by$345.1 million in 2024 compared to 2023, driven by a $340.0 million net increase in the acquisition of investments [487]. - The company plans to commit substantial resources to product acquisition, development, and expansion of operations [481]. Goodwill and Intangible Assets - As of December 31, 2024, the company had$1.7 billion of goodwill resulting from acquisitions accounted for as business combinations [531]. - The fair value of the reporting unit significantly exceeded its carrying amount, indicating no impairment of goodwill as of the annual test in October 2024 [531]. - The company expects to continue acquiring intangible assets, with fair values determined using discounted cash flow models [533]. - As of December 31, 2024, the company had $4.8 billion of finite-lived intangible assets, including$3.3 billion related to Epidiolex and $1.0 billion related to Vyxeos [537]. - No impairment charge was recognized for intangible assets in 2024 or 2023; however, a$133.6 million impairment charge was recorded in 2022 for the nabiximols program [538]. Foreign Exchange and Interest Rate Management - A hypothetical 10% strengthening or weakening in exchange rates would have increased or decreased net income by approximately $78.0 million for sterling and$3.3 million for euro [553]. - As of December 31, 2024, the net liability fair value of outstanding foreign exchange forward contracts was $7.9 million, with notional amounts totaling$461.2 million [554]. - The company entered into interest rate swap agreements with a notional amount of $500.0 million, fixing the interest rate on a portion of term loan borrowings at 3.9086$1.1 billion, $1.4 billion, and$1.0 billion, respectively, as of December 31, 2024 [552]. Tax Jurisdictions - The company has significant operations in Ireland, the U.K., and the U.S., which are its most significant tax jurisdictions [541].